WHAT’S NEW IN DIABETES Lisa Still, RN,CDE Diabetes Specialty Nurse Arkansas Children’s Hospital November 2011.

Slides:



Advertisements
Similar presentations
Medications Insulin. Without Insulin With Treatment of Insulin.
Advertisements

Advanced Pumping. Objectives: Identify situations to utilize temporary basal rate in pump therapy patients. Identify examples of when to use combination.
Newest Trends in Diabetes Management in Schools
1-800-DIABETES DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to Know DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to.
Introducing The SHINE Trial (Stroke Hyperglycemia Insulin Network Effort) An Overview for Clinical Nurses NIH-NINDS U01 NSO69498.
Diabetes Care Tasks at School: What Key Personnel Need to Know Diabetes Care Tasks at School: What Key Personnel Need to Know INSULIN ADMINISTRATION.
1-800-DIABETES DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to Know DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to.
Diabetes (abridged!). Who needs screening for DM? Age >45 Obese – BMI >25 1 st degree relative with DM Racial groups: –African American –Hispanic American.
Quick Pump Facts o Constantly provides insulin o Pager-sized “mini-computer” worn outside the body o Pump itself is attached to your body by a small cannula.
Canadian Diabetes Assocaition Clinical Practice Guidelines Pharmacotherapy in Type 1 Diabetes Chapter 12 Angela McGibbon, Cindy Richardson, Cheri Hernandez,
Continuous Glucose Monitoring. Diabetes Management Evolution Insulin Delivery Glucose Monitoring 2000 First CGM system 2006 Paradigm REAL- Time, combining.
Algorithm for the Treatment and Management of Hypoglycaemia in Adults with Diabetes Mellitus in Hospital Hypoglycaemia is a serious condition and should.
By Parker Grand. On March 26, 2012 I celebrated 10 years of HEALTHY living with Type 1 Diabetes 10 years includes... 40, 150 Finger sticks 9, 125 Injections.
Insulin Pump What to tell your patient!! Prakash Abraham Isla Fairley.
Continuous Glucose Monitoring
Artificial Pancreas By: Anas Syed.
Type 1 Diabetes Debbie McCausland Paediatric Diabetes Specialist Nurses.
A training module for school staff. What is Diabetes? A disease that causes the body to have trouble making and/or using insulin. Insulin, a hormone made.
You Have Diabetes! New Diagnosis Scared 15 year old… What are your fears? Who are your stakeholders?
1-800-DIABETES DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to Know DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to.
By Marissa Miuccio.  Type 1 diabetes, once known as juvenile diabetes or insulin-dependent diabetes, is a chronic condition in which the pancreas produces.
Management Tools and CGM Kathryn Moe, RN CDE Medtronic Diabetes.
Pumps and Sensors In the School Setting. 2 Agenda Comparison of available insulin pumps Continuous glucose monitors Pump therapy & CGM in the school setting.
SITUATION Hypoglycaemia – blood glucose level
INSULIN THERAPY IN TYPE 1 DIABETES
Management of Inpatient Blood Glucose at Temple Housestaff Orientation 2014.
Diabetes Technology Update
Diabetes: The Modern Epidemic Roy Buchinsky, MD Director of Wellness.
Endocrine Disorders in the Pediatric Client Susan Beggs, MSN, CPN Susan Beggs, MSN, CPN.
Type 1 Diabetes and the Family: Strategies for Success Jan 2009 Susan J. Clark, M.D. Children’s Hospital of Orange County Joe Solowiejczyk R.N., C.D.E.M.S.W.
Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.
Insulin Initiation In Primary Care Dr Arla Ogilvie Endocrinologist Watford General Hospital West Herts Hospitals NHS Trust.
Type I Diabetes Mellitus
INSULIN PUMPS Shelby Polk DNP, FNP-BC, CDE. 2 MANAGEMENT OF DIABETES IN SCHOOLS Exercise Legal Rights Health & Learning Nutrition Insulin Administration.
TALK DIABETES November 13, 2015 Pumping Insulin 101 Bonnie Stone-Hope RN, CDE, BA.
 Provide a high level overview of diabetes head to toe.  Discuss the importance of keeping A1Cs under 8.  Identify ways to prevent long-term complications.
18/11/20081 Diabetes mellitus Prepared by Thamer-almangour.
Opiate Analgesic Use in Pediatric Patients Bob Rappaport, M.D. Deputy Division Director Division of Anesthetic, Critical Care and Addiction Drug Products,
Insulin Elixir of life Dr. Sergio Diez Alvarez Staff Specialist Physician.
Diabetes Update: Michael Gottschalk, M.D, Ph.D.
Endocrine System KNH 411. Diabetes Mellitus 7% of population; 1/3 undiagnosed $132 billion in health care Sixth leading cause of death Complications of.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
What Key Personal Need To Know INSULIN ADMINISTRATION.
Focus on Diabetes Mellitus NUR 171. How insulin works dia2.us.elsevierhealth.com/ondemand/archieAnimations/423.flv.
January 2013 Standards of Care for Diabetes Management in the School Setting – Colorado January 2013.
Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,
Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth.
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomized open-label controlled trial Yves.
Types of Syringes Types of syringes are shown: A, 5-mL syringe. B, 3-mL syringe. C, Tuberculin syringe marked in 0.01 (hundredths) for doses less than.
A life-changing story of invention for people with diabetes Dan Quinn 21.
Dr Zaranyika MBChB(Hons) UZ, MPH, FCP SA Department of Medicine UZ-CHS
 History of advancement in diabetes treatment  New technology  Features  Pros and Cons  Safety in school  Questions.
Galen College of Nursing Gabriela Morris NUR 3150 Dr. Marion Johnson
Baseline characteristics
1-800-DIABETES DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to Know DIABETES CARE TASKS AT SCHOOL: What Key Personnel Need to.
Endocrine System KNH 411.
INSULIN BY PEN 12/2008.
Endocrine System KNH 411.
12/2008 INSULIN BY PUMP.
Continuous Subcutaneous Insulin Infusion (CSII) [Insulin Pump]
Endocrine System KNH 411.
Approach to starting and adjusting insulin in type 2 diabetes.
Endocrine System KNH 411.
Endocrine System KNH 411.
Introduction to Continuous Glucose Monitoring
Endocrine System KNH 411.
User-based design strategy
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
INSULIN BY PEN 12/2008.
Presentation transcript:

WHAT’S NEW IN DIABETES Lisa Still, RN,CDE Diabetes Specialty Nurse Arkansas Children’s Hospital November 2011

New devices Insulin pen devices Insulin pumps Cgm

Insulin Pens Easier for patients to carry with them. Discreet. Looks like an ink pen Easy storage and disposal Used only for one patient ( pen devices should not be shared between patients). Less likely to break if dropped when compared to vial.

Rapid acting insulin pens

Pen cartridges

Long acting insulin pens

Pen needles

Insulin pumps Continuous Subcutaneous Insulin Infusion (pump therapy) Subcutaneous delivery of insulin via external electro-mechanical device. Has small plastic cannula in sub q tissue. Delivery regimen mimics the basal/bolus delivery pattern of a pancreas. Can deliver various basal rates throughout the day. Allows flexibility of dosing for snacks without having to take additional injections.

Delivery is extremely precise. Pump accurately delivers doses down to unit of insulin REMEMBER.... The Insulin Pump is a computer. It can only do what the user tells it to do. Requires decisions from user. User requires Blood glucose data and carbohydrate content to make good decisions

Insulin pumps

Injection and pump site

Infusion sets Animas one touch ping Medtronic Omnipod

Un-tethered pump regimen Patient takes Lantus as basal. Connect to pump site for bolus. Allows patient to be “off pump” for extended time without extreme excursions. If patient forgets to take Lantus, will have ketones very quickly.

Continuous Glucose Monitoring Overview Continuous Glucose Monitoring (CGM) consists of a glucose sensor, a transmitter, and a small external monitor (may be built-in to an insulin pump or a stand- alone device) to view your glucose levels.

Why CGM? Continuous Glucose Monitoring (CGM) provides more complete information than finger sticks, helping you to make better decisions, which leads to better glucose control. In fact, finger sticks can miss many of the potentially dangerous highs and lows that may occur throughout the day, which can impact your glucose control. CGM can provide valuable information at crucial points during the day. This includes before and during exercise, prior to driving, prior to test/exam-taking, and in the middle of the night. It is still required to check blood glucose levels with a finger stick before administering insulin.

Benefits of CGM Some specific benefits of adding CGM to your diabetes therapy management include: Easily knowing your glucose levels at all times Anticipating glucose level changes Being able to avoid upcoming lows and highs Easily finding glucose patterns Also, CGM has been proven to be an effective tool to: Reduce the frequency and duration of highs and lows Reduce A1C, which can lead to reduced risk of complications Reduce A1C without increase to extreme lows

CGM Dexcom Partnered with Animas and omnipod In the future Medtronic

Type 2 Diabetes Typically seen in obese and overweight children who are physically inactive Increasing in epidemic proportions. Caused by both genetics and environmental factors. 50%-80% have a parent with a family history of type 2 diabetes. Will possibly be the next cause of morbidity and mortality in the next generation. Occurs as a result of insulin resistance and some insulin deficiency. Insulin resistance occurs when the liver and muscles are not sensitive to the insulin that is being produced.

Acanthosis Nigricans

Treatment for Type 2 diabetes Meal planning- we will give them a set meal plan with a cap on carbs. Increased activity- Need at least 30 minutes of physical activity every day. Metformin (Glucophage)- only tablet that is FDA approved for use with children over 12. None for children under 12. Insulin- Basal/Bolus with the hope of tapering off of insulin completely.

Research Research studies that we are doing currently for type 1 diabetes is TrialNet. Screening first and second degree relatives between the ages of 1-45 for autoantiboidies for T1DM. There are 3 clinical trials that we are participating in for T2DM. The first one is a Daiichi Sankyo study the use of colesevelam oral suspension as monotherapy or add-on to metformin in pediatric subjects. Colesevelam is marketed for adults as an adjunct to diet and exercise to reduce LDL-cholesterol in patients with hyperlipidemia. Adult studies has shown that colesevelam in addition to pre-existing anti-diabetic therapy significantly reduces A1c. The other studies we are involved with are 2 studies are Evaluating the Safety and Efficacy of Sitagliptin in Pediatric Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control. Again Sitaglipitin is an FDA approved drug that is used in conjunction with Metromin in adults with type 2 diabetes.

Contact information The best way to manage diabetes is to communicate with the team. Parents/caregivers can contact us by: Phone or Fax web based log book

References ethered.htm ethered.htm tcoyd.org/tcoyd-team/steven-v.- edelman-md.html